U.S./EU mutual recognition agreement
This article was originally published in The Gray Sheet
Executive Summary
Changes to the list of devices covered under the MRA should be approved by the European Commission rather than by each European member state, the Health Industry Manufacturers Association says in a Sept. 30 letter to U.S. State Department Ambassador Stuart Eizenstat. HIMA expresses concern that allowing each member to consider the issue "could create problems and result in significant delays in implementation of the MRA." Both FDA and the EU have expressed a willingness to expand the current MRA device list to match the products covered under the agency's domestic third party "Accredited Persons" program
You may also be interested in...
Who’s Hired? Hikma Recruits New US Generics President
A flurry of top level recruitments made headlines in the past weeks, with the likes of Hikma, Lupin, and Viatris announcing new hires while focusing on their targets for the year.
Organon And Henlius Complete Phase III For Denosumab
Having earlier this year reported positive Phase I data for their partnered denosumab biosimilar candidate, Organon and Shanghai Henlius Biotech have now announced that their HLX14 version has met primary endpoints in a Phase III study.
Taro Agrees $36m Securities Settlement Over US Price-Fixing Claims
Sun’s Taro subsidiary is looking to move forward with an eight-figure settlement deal in the US, after plaintiffs including a firefighters’ pension fund accused the firm of misleading investors via its involvement in generic price fixing, leading to a fall in the price of its securities.